Wai Yuen Tong Medicine Holdings Past Earnings Performance
Past criteria checks 0/6
Wai Yuen Tong Medicine Holdings's earnings have been declining at an average annual rate of -36.3%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 11.7% per year.
Key information
-36.3%
Earnings growth rate
-36.3%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | 11.7% |
Return on equity | -0.5% |
Net Margin | -3.4% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too
Jul 26Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
Mar 11The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business
Dec 28Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Jul 11Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt
Jul 05Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Mar 08Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now
Aug 18Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Mar 17Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares
Jan 22Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Dec 16Revenue & Expenses Breakdown
How Wai Yuen Tong Medicine Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 784 | -27 | 354 | 0 |
30 Sep 23 | 1,359 | 36 | 544 | 0 |
30 Jun 23 | 1,323 | 8 | 544 | 0 |
31 Mar 23 | 724 | -16 | 337 | 0 |
31 Dec 22 | 1,314 | -98 | 532 | 0 |
30 Sep 22 | 1,341 | -176 | 520 | 0 |
30 Jun 22 | 1,366 | -143 | 512 | 0 |
31 Mar 22 | 1,391 | -109 | 505 | 0 |
31 Dec 21 | 1,323 | -122 | 492 | 0 |
30 Sep 21 | 1,255 | -135 | 480 | 0 |
30 Jun 21 | 1,182 | -255 | 454 | 0 |
31 Mar 21 | 1,109 | -376 | 428 | 0 |
31 Dec 20 | 979 | -98 | 427 | 0 |
30 Sep 20 | 849 | 179 | 426 | 0 |
30 Jun 20 | 735 | 309 | 420 | 0 |
31 Mar 20 | 621 | 439 | 415 | 0 |
31 Dec 19 | 655 | 253 | 413 | 0 |
30 Sep 19 | 689 | 66 | 412 | 0 |
30 Jun 19 | 720 | 71 | 430 | 0 |
31 Mar 19 | 751 | 75 | 449 | 0 |
31 Dec 18 | 779 | 20 | 458 | 0 |
30 Sep 18 | 807 | -35 | 468 | 0 |
30 Jun 18 | 826 | -75 | 462 | 0 |
31 Mar 18 | 846 | -116 | 456 | 0 |
31 Dec 17 | 808 | -106 | 443 | 0 |
30 Sep 17 | 770 | -96 | 430 | 0 |
30 Jun 17 | 754 | -94 | 433 | 0 |
31 Mar 17 | 738 | -93 | 436 | 0 |
31 Dec 16 | 769 | -87 | 442 | 0 |
30 Sep 16 | 799 | -81 | 447 | 0 |
30 Jun 16 | 812 | -28 | 445 | 0 |
31 Mar 16 | 825 | 25 | 443 | 0 |
30 Sep 15 | 827 | 177 | 424 | 0 |
30 Jun 15 | 829 | 149 | 416 | 0 |
31 Mar 15 | 831 | 121 | 408 | 0 |
30 Sep 14 | 835 | 120 | 384 | 0 |
30 Jun 14 | 850 | 144 | 376 | 0 |
31 Mar 14 | 865 | 168 | 368 | 0 |
Quality Earnings: 897 is currently unprofitable.
Growing Profit Margin: 897 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 897 is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.
Accelerating Growth: Unable to compare 897's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 897 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).
Return on Equity
High ROE: 897 has a negative Return on Equity (-0.53%), as it is currently unprofitable.